GeneThera (GeneThera) Risk Assessment

View and export this data going back to 2000. Start your Free Trial

What is GeneThera Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of GeneThera is: No Data: Cannot be evaluated.

Competitive Comparison of GeneThera's Risk Assessment

For the Biotechnology subindustry, GeneThera's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeneThera's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneThera's Risk Assessment distribution charts can be found below:

* The bar in red indicates where GeneThera's Risk Assessment falls into.

GeneThera (OTCPK:GTHR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

GeneThera Risk Assessment Related Terms

Thank you for viewing the detailed overview of GeneThera's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneThera (GeneThera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035

Website

http://genetherainc.com

GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.

Executives

Avel Kolesnikov	director	11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr	10 percent owner	632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd	10 percent owner	CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner	director, officer: Chief Financial Officer	728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici	director, 10 percent owner, officer: Chief Executive Officer	3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry	director, 10 percent owner, officer: Chief Administative Officer	11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines